Calibr-Skaggs Announces Expansion of Option and License Agreement With AbbVie to Develop Novel Cell Therapies for Solid Tumors and Autoimmune Diseases

0
31
The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development division of Scripps Research, announced that AbbVie has expanded its collaboration to further explore Calibr-Skaggs’ switchable CAR-T platform in solid tumor indications and autoimmune diseases.
[Scripps Research]
Press Release